The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States…
Complete list of ACIP recommendations published in the MMWR.
Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
GRADE (Grading of Recommendations Assessment, Development & Evaluation)
Find tables referenced in ACIP recommendations published in MMWR and learn about GRADE.
General Committee-related Information
Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
Nominations for future vacancies on ACIP
Procedure for nomination of candidates for ACIP membership.
- Nominations for future vacancies on ACIP
Journal articles about the ACIP.
ACIP Guidance for Economics Studies
Procedures for review of economic analyses to be presented to the ACIP.
ACIP Guidance for Vaccine Recommendations for Pregnant & Breastfeeding Women
Guiding principles for development of ACIP recommendations for vaccination of pregnant and breastfeeding women.
- ACIP Vaccine Acronyms
This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?
On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B, for use in adults 18 years of age and older. HEPLISAV-B is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart. Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States.
*Cytosine phosphoguanine (CpG) 1018 adjuvant
October 2017 Meeting Recommendations
ACIP approved the following recommendations by majority vote at its October 2017 meeting:
- The 2018 adult immunization schedule, for adults 19 years of age and older;
- The 2018 child and adolescent immunization schedules, for children 18 years of age and younger;
- Use of a third dose of mumps-containing vaccine for persons identified by public health as at increased risk for mumps because of an outbreak;
- Use of Herpes Zoster subunit vaccine (Shingrix®) for the prevention of herpes zoster and its related complications for immunocompetent adults 50 years of age and older;
- Use of Herpes Zoster subunit vaccine for immunocompetent adults who previously received Zoster Vaccine Live (Zostavax®); and
- Preference for Herpes Zoster subunit vaccine over Zoster Vaccine Live.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.
- Page last reviewed: April 15, 2016
- Page last updated: February 13, 2018
- Content source: